Dashboard
1
Poor Management Efficiency with a low ROCE of 2.43%
- The company has been able to generate a Return on Capital Employed (avg) of 2.43% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 2.50% and Operating profit at -145.85% over the last 5 years
4
The company has declared Negative results for the last 6 consecutive quarters
5
With ROE of 0.17%, it has a risky valuation with a 1.81 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,895 Million (Mid Cap)
1,093.00
NA
0.00%
0.41
0.17%
1.81
Revenue and Profits:
Net Sales:
687 Million
(Quarterly Results - Jun 2025)
Net Profit:
28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.15%
0%
-10.15%
6 Months
29.53%
0%
29.53%
1 Year
29.21%
0%
29.21%
2 Years
-36.8%
0%
-36.8%
3 Years
-36.8%
0%
-36.8%
4 Years
-11.22%
0%
-11.22%
5 Years
-40.82%
0%
-40.82%
Guizhou Bailing Group Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.50%
EBIT Growth (5y)
-145.85%
EBIT to Interest (avg)
0.17
Debt to EBITDA (avg)
7.58
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
0.73
Tax Ratio
50.71%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.43%
ROE (avg)
1.63%
Valuation key factors
Factor
Value
P/E Ratio
1093
Industry P/E
Price to Book Value
1.81
EV to EBIT
-1151.02
EV to EBITDA
63.59
EV to Capital Employed
1.58
EV to Sales
2.33
PEG Ratio
10.81
Dividend Yield
NA
ROCE (Latest)
-0.14%
ROE (Latest)
0.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
687.50
797.00
-13.74%
Operating Profit (PBDIT) excl Other Income
105.80
103.60
2.12%
Interest
14.70
24.30
-39.51%
Exceptional Items
0.00
0.00
Consolidate Net Profit
28.10
33.10
-15.11%
Operating Profit Margin (Excl OI)
112.10%
90.60%
2.15%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -13.74% vs -0.15% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -15.11% vs 10.70% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,776.50
4,213.10
-10.36%
Operating Profit (PBDIT) excl Other Income
178.50
-293.40
160.84%
Interest
86.00
93.10
-7.63%
Exceptional Items
75.30
6.70
1,023.88%
Consolidate Net Profit
36.80
-412.50
108.92%
Operating Profit Margin (Excl OI)
14.20%
-99.10%
11.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.36% vs 20.69% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 108.92% vs -402.86% in Dec 2023
About Guizhou Bailing Group Pharmaceutical Co., Ltd. 
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






